Quest Diagnostics earnings release, July 23, 2026

Quest Diagnostics Inc (DGX) · Form 8-K, Item 2.02 · Filed · SEC filing

Quest Diagnostics Reports Second Quarter 2026 Financial Results;

Raises Revenue and EPS Guidance for Full Year 2026

• Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth

• Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025

• Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion

• Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25

SECAUCUS, N.J., July 23, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.

“Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health,” said Jim Davis, Chairman, CEO and President. “Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance.”

Recent Highlights:

Serving Customers and Delivering Innovations

• Continued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan and developed new capabilities in kidney care through our collaboration with Fresenius Medical Care in the United States.

• Generated robust revenue growth through questhealth.com and our consumer, wearable and wellness partners.

• Grew revenues by double-digits in several areas of Advanced Diagnostics, including Quest AD-Detect® blood tests for Alzheimer’s disease and advanced cardiometabolic and endocrine tests, including liver fibrosis testing.

• Granted New York State approval for our Haystack MRD® test and became the largest reference lab to utilize Flatiron Health's OncoEMR® Molecular Profiling Integration (MPI) platform for select cancer tests, including Haystack MRD, starting with a pilot with American Oncology Network (AON).

Driving Operational Excellence

• In the lab, extended automation solutions to improve quality and productivity in cervical cancer screening and front-end specimen processing to additional labs.

• Outside the lab, launched IntelliDraw™ to guide clinical staff of our physician customers through specimen collection, to enhance quality and the service experience.¹

(a)

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Updated Guidance for Full Year 2026

The company updates its full year 2026 guidance as follows:

Based on the favorable resolution of various tax contingencies in the second quarter, the full year adjusted effective tax rate is expected to be consistent with 2025.

Note on Non-GAAP Financial Measures

As used in this press release the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.²

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on July 23, 2026 until midnight Eastern Time on August 6, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About Quest Diagnostics... (truncated)f the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended June 30, (dollars in millions, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Three Months Ended June 30, – ChangeSix Months Ended June 30, – 2026Six Months Ended June 30, – 2025Six Months Ended June 30, – Change
Reported:Net revenues3,0432,76110.25,9385,4139.7
Reported:Diagnostic Information Services revenues2,9782,69910.35,8105,2889.9
Reported:Revenue per requisition-2.8-2.1
Reported:Requisition volume13.112
Reported:Organic requisition volume1311.9
Reported:Operating income (a)4594384.68587849.4
Reported:Operating income as a percentage of net revenues (a)15.1%15.9%-0.814.4%14.5%-0.1
Reported:Net income attributable to Quest Diagnostics (a)32028213.457250213.9
Reported:Diluted EPS (a)2.842.47155.084.4115.2
Reported:Cash provided by operations5975449.78758581.9
Reported:Capital expenditures1381082725222512.1
Adjusted (a):Operating income5024667.89498728.8
Adjusted (a):Operating income as a percentage of net revenues16.5%16.9%-0.416.0%16.1%-0.1
Adjusted (a):Net income attributable to Quest Diagnostics35029817.363154914.9
Adjusted (a):Diluted EPS3.122.6219.15.624.8316.4

Income Statement

The company updates its full year 2026 guidance as follows:

Updated Guidance – LowUpdated Guidance – HighPrior Guidance – LowPrior Guidance – High
Net revenues$11.95 billion$12.05 billion$11.78 billion$11.90 billion
Net revenues increase8.3%9.2%6.8%7.8%
Reported diluted EPS9.9710.179.589.78
Adjusted diluted EPS11.0511.2510.6310.83
Cash provided by operationsApproximately $1.80 billionApproximately $1.75 billion
Capital expendituresApproximately $550 millionApproximately $550 million

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenues3,0432,7615,9385,413
Operating costs and expenses and other operating income:Cost of services2,0161,8183,9693,607
Operating costs and expenses and other operating income:Selling, general and administrative5294861,033962
Operating costs and expenses and other operating income:Amortization of intangible assets38397578
Operating costs and expenses and other operating income:Other operating expense (income), net1-203-18
Operating costs and expenses and other operating income:Total operating costs and expenses, net2,5842,3235,0804,629
Operating costs and expenses and other operating income:Operating income459438858784
Other income (expense):Interest expense, net-63-67-126-134
Other income (expense):Other income, net16131410
Other income (expense):Total non-operating expense, net-47-54-112-124
Other income (expense):Income before income taxes and equity in earnings of equity method investees412384746660
Other income (expense):Income tax expense-88-97-162-156
Other income (expense):Equity in earnings of equity method investees, net of taxes1091427
Other income (expense):Net income334296598531
Other income (expense):Less: Net income attributable to noncontrolling interests14142629
Other income (expense):Net income attributable to Quest Diagnostics320282572502
Earnings per share attributable to Quest Diagnostics’ common stockholders:Basic2.882.515.154.48
Earnings per share attributable to Quest Diagnostics’ common stockholders:Diluted2.842.475.084.41
Weighted average common shares outstanding:Basic111112110112
Weighted average common shares outstanding:Diluted112113112113

Income Statement

Three Months Ended June 30, — The computation of basic and diluted earnings per common share is as follows: (in millions, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Amounts attributable to Quest Diagnostics' common stockholders:Net income attributable to Quest Diagnostics320282572502
Amounts attributable to Quest Diagnostics' common stockholders:Less: earnings allocated to participating securities1122
Amounts attributable to Quest Diagnostics' common stockholders:Earnings available to Quest Diagnostics' common stockholders - basic and diluted319281570500
Amounts attributable to Quest Diagnostics' common stockholders:Weighted average common shares outstanding - basic111112110112
Effect of dilutive securities:Stock options and performance share units1121
Effect of dilutive securities:Weighted average common shares outstanding - diluted112113112113
Earnings per share attributable to Quest Diagnostics' common stockholders:Basic2.882.515.154.48
Earnings per share attributable to Quest Diagnostics' common stockholders:Diluted2.842.475.084.41

Income Statement

Six Months Ended June 30, 2026 — The following tables reconcile reported GAAP results to non-GAAP adjusted results: (dollars in millions, except per share data)

Six Months Ended June 30, 2026 – Operating incomeSix Months Ended June 30, 2026 – Operating income as a percentage of net revenuesSix Months Ended June 30, 2026 – Income tax expense (e)Six Months Ended June 30, 2026 – Equity in earnings of equity method investees, net of taxesSix Months Ended June 30, 2026 – Net income attributable to Quest DiagnosticsSix Months Ended June 30, 2026 – Diluted EPS
As reported85814.4-162145725.08
Restructuring and integration charges (a)110.2-380.08
Other charges (b)50.150.05
Gains and losses on investments (c)-2640.04
Amortization expense751.3-19560.5
ETB-14-14-0.13
As adjusted94916-200206315.62

Income Statement

Three Months Ended June 30, 2025 — The following tables reconcile reported GAAP results to non-GAAP adjusted results: (dollars in millions, except per share data)

Three Months Ended June 30, 2025 – Operating incomeThree Months Ended June 30, 2025 – Operating income as a percentage of net revenuesThree Months Ended June 30, 2025 – Income tax expense (e)Three Months Ended June 30, 2025 – Equity in earnings of equity method investees, net of taxesThree Months Ended June 30, 2025 – Net income attributable to Quest DiagnosticsThree Months Ended June 30, 2025 – Diluted EPS
As reported43815.9-9792822.47
Restructuring and integration charges (a)70.3-250.04
Other charges (b)281-6220.19
Gains and losses on investments (c)1-1-2-0.01
Other gains (d)-46-1.712-34-0.3
Amortization expense391.4-11280.25
ETB-3-3-0.02
As adjusted46616.9-10682982.62

Income Statement

Six Months Ended June 30, 2025 — The following tables reconcile reported GAAP results to non-GAAP adjusted results: (dollars in millions, except per share data)

Six Months Ended June 30, 2025 – Operating incomeSix Months Ended June 30, 2025 – Operating income as a percentage of net revenuesSix Months Ended June 30, 2025 – Income tax expense (e)Six Months Ended June 30, 2025 – Equity in earnings of equity method investees, net of taxesSix Months Ended June 30, 2025 – Net income attributable to Quest DiagnosticsSix Months Ended June 30, 2025 – Diluted EPS
As reported78414.5-156275024.41
Restructuring and integration charges (a)260.5-7190.17
Other charges (b)300.6-6240.21
Gains and losses on investments (c)1-1-2-0.01
Other gains (d)-46-0.914-8-40-0.36
Amortization expense781.4-20580.51
ETB-12-12-0.1
As adjusted87216.1-186185494.83

Income Statement

Three Months Ended June 30, (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cost of services1127
Selling, general and administrative36919
Operating income471126

Balance Sheet

(unaudited)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents626420
Current assets:Accounts receivable, net1,6661,408
Current assets:Inventories233189
Current assets:Prepaid expenses and other current assets319361
Current assets:Total current assets2,8442,378
Current assets:Property, plant and equipment, net2,2192,203
Current assets:Operating lease right-of-use assets678657
Current assets:Goodwill9,1128,945
Current assets:Intangible assets, net1,6721,636
Current assets:Investments in equity method investees137136
Current assets:Other assets277270
Current assets:Total assets16,93916,225
Current liabilities:Accounts payable and accrued expenses1,5981,600
Current liabilities:Current portion of long-term debt10504
Current liabilities:Current portion of long-term operating lease liabilities180174
Current liabilities:Total current liabilities1,7882,278
Current liabilities:Long-term debt5,6325,167
Current liabilities:Long-term operating lease liabilities561537
Current liabilities:Other liabilities1,059957
Current liabilities:Redeemable noncontrolling interest8080
Quest Diagnostics stockholders’ equity:Common stock, par value $0.01 per share; 600 shares authorized as of both June 30, 2026 and December 31, 2025; 162 shares issued as of both June 30, 2026 and December 31, 202522
Quest Diagnostics stockholders’ equity:Additional paid-in capital2,3742,381
Quest Diagnostics stockholders’ equity:Retained earnings10,3749,994
Quest Diagnostics stockholders’ equity:Accumulated other comprehensive loss-62-27
Quest Diagnostics stockholders’ equity:Treasury stock, at cost; 52 shares as of both June 30, 2026 and December 31, 2025-5,172-5,180
Quest Diagnostics stockholders’ equity:Total Quest Diagnostics stockholders’ equity7,5167,170

Cash Flow

Six Months Ended June 30, — (unaudited)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net income598531
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization293283
Adjustments to reconcile net income to net cash provided by operating activities:Provision for credit losses32
Adjustments to reconcile net income to net cash provided by operating activities:Deferred income tax expense468
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation expense4343
Adjustments to reconcile net income to net cash provided by operating activities:Other, net1426
Changes in operating assets and liabilities:Accounts receivable-259-115
Changes in operating assets and liabilities:Accounts payable and accrued expenses130-11
Changes in operating assets and liabilities:Income taxes payable49
Changes in operating assets and liabilities:Other assets and liabilities, net382
Changes in operating assets and liabilities:Net cash provided by operating activities875858
Cash flows from investing activities:Business acquisitions, net of cash acquired-38-17
Cash flows from investing activities:Capital expenditures-252-225
Cash flows from investing activities:Other investing activities, net43
Cash flows from investing activities:Net cash used in investing activities-286-239
Cash flows from financing activities:Proceeds from borrowings494400
Cash flows from financing activities:Repayments of debt-501-1,001
Cash flows from financing activities:Purchases of treasury stock-102
Cash flows from financing activities:Exercise of stock options8142
Cash flows from financing activities:Employee payroll tax withholdings on stock issued under stock-based compensation plans-38-42
Cash flows from financing activities:Dividends paid-184-174
Cash flows from financing activities:Distributions to noncontrolling interest partners-22-29
Cash flows from financing activities:Other financing activities, net-109-50
Cash flows from financing activities:Net cash used in financing activities-381-854
Cash flows from financing activities:Effect of exchange rate changes on cash and cash equivalents and restricted cash-25
Cash flows from financing activities:Net change in cash and cash equivalents and restricted cash206-230
Cash flows from financing activities:Cash and cash equivalents and restricted cash, beginning of period420549
Cash flows from financing activities:Cash and cash equivalents and restricted cash, end of period626319
Cash paid during the period for:Interest129145
Cash paid during the period for:Income taxes104110
Full release

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

For further information: Wendy Bost, Quest Diagnostics (Media): 973-520-2800, Daniel Haemmerle, Quest Diagnostics (Investors): 973-520-2900

This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.

ADDITIONAL TABLES FOLLOW³

Quest Diagnostics Incorporated and Subsidiaries

Consolidated Statements of Operations

For the Three and Six

Months Ended June 30, 2026 and 2025

(in millions, except per share data)

(unaudited)⁴

Quest Diagnostics Incorporated and Subsidiaries

Consolidated Balance Sheets

June 30, 2026 and December 31, 2025

(in millions, except per share data)

(unaudited)⁵

Quest Diagnostics Incorporated and Subsidiaries

Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2026 and 2025

(in millions)

(unaudited)⁶

Notes to Financial Tables

1)

The computation of basic and diluted earnings per common share is as follows:

2)

The following tables reconcile reported GAAP results to non-GAAP adjusted results:⁷⁸

(a)

For each of the three and six months ended June 30, 2026 and 2025, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:

(b)

The three and six months ended June 30, 2026 and 2025 include losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions, recorded in other operating expense (income), net. Additionally, for both the three and six months ended June 30, 2025, the pre-tax impact primarily represents a $24 million impairment charge on certain long-lived assets related to the exit of a business, recorded in other operating expense (income), net.

(c)

For all periods presented, the pre-tax impact represents gains and losses associated with changes in the carrying value of our strategic investments, principally recorded in equity in earnings of equity method investees, net of taxes, and other income, net.

(d)

The three and six months ended June 30, 2025 include a $46 million pre-tax gain, recorded in other operating expense (income), net, from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act associated with the retention of employees. Additionally, the six months ended June 30, 2025 includes an $8 million gain, recorded in equity in earnings of equity method investees, net of taxes, representing a non-recurring gain related to a lease.

(e)

For restructuring and integration charges, other gains/charges, gains and losses on investments, and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2026 and 2025. No income tax impact was recorded on losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions.

3)

For both the three and six months ended June 30, 2026, we repurchased 0.5 million shares of our common stock for $100 million. As of June 30, 2026, $1.3 billion remained available under our share repurchase authorization.

4)

The outlook for adjusted diluted EPS represents management’s estimates for the full year 2026 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2026. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2026 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS:

(a)

Represents estimated pre-tax charges of $21 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.

(b)

Represents estimated pre-tax amortization expenses of $149 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.⁹

(c)... (truncated) of $9 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions. Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above. No income tax benefits are recorded on the changes associated with the contingent consideration accrual.

(d)

Income tax impacts were calculated using a combined statutory income tax rate of 25.5%.¹⁰

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Quest Diagnostics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.